Sotalol in neonates for arrhythmias: Dosing, safety, and efficacy.
neonate
sotalol
supraventricular tachycardia
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
17
04
2023
received:
22
02
2023
accepted:
08
05
2023
medline:
12
6
2023
pubmed:
21
5
2023
entrez:
21
5
2023
Statut:
ppublish
Résumé
Various agents may be utilized to manage supraventricular tachycardia (SVT) in neonates and infants. Recently, sotalol has piqued interest given its reported success in managing neonates and infants with SVTs, especially with the intravenous formulation. While the manufacturer recommends using an age-related nomogram in neonates and young infants to guide doses, clinical reports describe various dosing based on weight (mg/kg) or on body surface area (BSA) in mg/m This is a single center retrospective study evaluating effective sotalol dosing from January 2011 and June 2021 (inclusive). Neonates who received intravenous (IV) or oral (PO) sotalol for SVT were eligible for inclusion. The primary outcome was to describe sotalol doses based on body weight and BSA. Secondary outcomes include comparison of doses to the manufacturer nomogram, description of dose titrations, reported adverse outcomes, and change in therapy. Two-sided Wilcoxon signed-rank tests were used to determine statistically significant differences. Thirty-one eligible patients were included in this study. The median (range) age and weight were 16.5 (1-28) days and 3.2 (1.8-4.9) kg, respectively. The median initial dose was 7.3 (1.9-10.8) mg/kg or 114.3 (30.9-166.7) mg/m This study demonstrates that a sotalol strategy significantly higher than the manufacture dose recommendations are required for rhythm control in neonates with SVT. There were few adverse events reported with this dosing. Further prospective studies would be advantageous to confirm these findings.
Substances chimiques
Sotalol
A6D97U294I
Anti-Arrhythmia Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1459-1463Informations de copyright
© 2023 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC.
Références
Chu PY, Hill KD, Clark RH, Brian Smith P, Hornik CP. Treatment of supraventricular tachycardia in infants: analysis of a large multicenter database. Early Hum Dev. 2015;91(6):345-350. doi:10.1016/j.earlhumdev.2015.04.001
Borquez AA, Aljohani OA, Williams MR, Perry JC. Intravenous sotalol in the young. JACC. 2020;6(4):425-432.
Seslar SP, Garrison MM, Larison C, Salerno JC. A multi-institutional analysis of inpatient treatment for supraventricular tachycardia in newborns and infants. Pediatr Cardiol. 2013;34(2):408-414.
Wong KK, Potts JE, Etheridge SP, Sanatani S. Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol. 2006;27(2):199-203.
Kim H, Wolff J, Dalal A, Van Hare GF, Avari Silva JN. Use of intravenous sotalol in newborns with supraventricular tachycardia. HeartRhythm Case Rep. 2017;3(7):332-335.
Tanel RE, Walsh EP, Lulu JA, Saul JP. Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. Am Heart J. 1995;130(4):791-797.
Maragnès P, Tipple M, Fournier A. Effectiveness of oral sotalol for treatment of pediatric arrhythmias. Am J Cardiol. 1992;69(8):751-754.
Colloridi V, Perri C, Ventriglia F, Critelli G. Oral sotalol in pediatric atrial ectopic tachycardia. Am Heart J. 1992;123(1):254-256.
Tipple M, Sandor G. Efficacy and safety of oral sotalol in early infancy. Pacing Clin Electrophysiol. 1991;14(11 Pt 2):2062-2065.
Celiker A, Ayabakan C, Ozer S, Ozme S. Sotalol in treatment of pediatric cardiac arrhythmias. Pediatr Int. 2001;43(6):624-630.
Li X, Zhang Y, Liu H, Jiang H, Ge H, Zhang Y. Efficacy of intravenous sotalol for treatment of incessant tachyarrhythmias in children. Am J Cardiol. 2017;119(9):1366-1370.
Sotalol. LexiComp. Indianapolis. Wolters Kluwer Health; 2021.
Li X, Zhang Y, Liu H, Jiang H, Ge H, Zhang Y. Pediatric dosing of intravenous sotalol based on body surface area in patients with arrhythmia. Pediatr Cardiol. 2017;38(7):1450-1455.
Läer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol. 2005;46(7):1322-1330.
Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn. 2001;28(6):555-575.
Saul J. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Clin Pharm Ther. 2001;69(3):145-157.
Saul JP, Schaffer MS, Karpawich PP, et al. Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. J Clin Pharmacol. 2001;41(1):35-43.
Knudson JD, Cannon BC, Kim JJ, Moffett BS. High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol. 2011;32(7):896-903.
Valdés SO, Miyake CY, Niu MC, et al. Early experience with intravenous sotalol in children with and without congenital heart disease. Heart Rhythm. 2018;15(12):1862-1869. doi:10.1016/j.hrthm.2018.07.010
Valdés SO, Landstrom AP, Schneider AE, Miyake CY, de la Uz CM, Kim JJ. Intravenous sotalol for the management of postoperative junctional ectopic tachycardia. HeartRhythm Case Rep. 2018;4(8):375-377. doi:10.1016/j.hrcr.2018.05.007
Malloy-Walton LE, Von Bergen NH, Balaji S, et al. IV sotalol use in pediatric and congenital heart patients: a multicenter registry study. J Am Heart Assoc. 2022;11(9):e024375.